Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Michael Gold, Joan Amatniek, Maria C. Carrillo, Jesse M. Cedarbaum, James A. Hendrix, Bradley B. Miller, Julie M. Robillard, J. Jeremy Rice, Holly Soares, Maria B. Tome, Ioannis Tarnanas, Gabriel Vargas, Lisa J. Bain, Sara J Czaja

Research output: Contribution to journalShort survey

8 Citations (Scopus)

Abstract

Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.

Original languageEnglish (US)
Pages (from-to)234-242
Number of pages9
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Alzheimer Disease
Biomarkers
Outcome Assessment (Health Care)
Clinical Trials
Technology
Research
Cognition
Dementia
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Clinical trials
  • Cognition
  • Digital technology
  • Function

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. / Gold, Michael; Amatniek, Joan; Carrillo, Maria C.; Cedarbaum, Jesse M.; Hendrix, James A.; Miller, Bradley B.; Robillard, Julie M.; Rice, J. Jeremy; Soares, Holly; Tome, Maria B.; Tarnanas, Ioannis; Vargas, Gabriel; Bain, Lisa J.; Czaja, Sara J.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 4, 01.01.2018, p. 234-242.

Research output: Contribution to journalShort survey

Gold, M, Amatniek, J, Carrillo, MC, Cedarbaum, JM, Hendrix, JA, Miller, BB, Robillard, JM, Rice, JJ, Soares, H, Tome, MB, Tarnanas, I, Vargas, G, Bain, LJ & Czaja, SJ 2018, 'Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 4, pp. 234-242. https://doi.org/10.1016/j.trci.2018.04.003
Gold, Michael ; Amatniek, Joan ; Carrillo, Maria C. ; Cedarbaum, Jesse M. ; Hendrix, James A. ; Miller, Bradley B. ; Robillard, Julie M. ; Rice, J. Jeremy ; Soares, Holly ; Tome, Maria B. ; Tarnanas, Ioannis ; Vargas, Gabriel ; Bain, Lisa J. ; Czaja, Sara J. / Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018 ; Vol. 4. pp. 234-242.
@article{e43ab713accb4d3e8121104645557469,
title = "Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials",
abstract = "Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.",
keywords = "Alzheimer's disease, Biomarkers, Clinical trials, Cognition, Digital technology, Function",
author = "Michael Gold and Joan Amatniek and Carrillo, {Maria C.} and Cedarbaum, {Jesse M.} and Hendrix, {James A.} and Miller, {Bradley B.} and Robillard, {Julie M.} and Rice, {J. Jeremy} and Holly Soares and Tome, {Maria B.} and Ioannis Tarnanas and Gabriel Vargas and Bain, {Lisa J.} and Czaja, {Sara J}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.trci.2018.04.003",
language = "English (US)",
volume = "4",
pages = "234--242",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

AU - Gold, Michael

AU - Amatniek, Joan

AU - Carrillo, Maria C.

AU - Cedarbaum, Jesse M.

AU - Hendrix, James A.

AU - Miller, Bradley B.

AU - Robillard, Julie M.

AU - Rice, J. Jeremy

AU - Soares, Holly

AU - Tome, Maria B.

AU - Tarnanas, Ioannis

AU - Vargas, Gabriel

AU - Bain, Lisa J.

AU - Czaja, Sara J

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.

AB - Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.

KW - Alzheimer's disease

KW - Biomarkers

KW - Clinical trials

KW - Cognition

KW - Digital technology

KW - Function

UR - http://www.scopus.com/inward/record.url?scp=85048302510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048302510&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2018.04.003

DO - 10.1016/j.trci.2018.04.003

M3 - Short survey

AN - SCOPUS:85048302510

VL - 4

SP - 234

EP - 242

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -